Full metadata record
DC FieldValueLanguage
dc.contributor.authorKREYLING WOLFGANGen_GB
dc.contributor.authorHOLZWARTH UWEen_GB
dc.contributor.authorHIRN STEPHANIEen_GB
dc.contributor.authorKOZEMPEL J.en_GB
dc.contributor.authorWENK A.en_GB
dc.contributor.authorHABERL NADINEen_GB
dc.contributor.authorSCHLEH CARSTENen_GB
dc.contributor.authorSCHAEFFLER MARTINen_GB
dc.contributor.authorLIPKA JENSen_GB
dc.contributor.authorSEMMLER-BEHNKE MANUELAen_GB
dc.contributor.authorGIBSON PETERen_GB
dc.date.accessioned2017-04-29T00:39:53Z-
dc.date.available2017-04-27en_GB
dc.date.available2017-04-29T00:39:53Z-
dc.date.created2017-04-04en_GB
dc.date.issued2017en_GB
dc.date.submitted2017-01-24en_GB
dc.identifier.citationNANOTOXICOLOGYen_GB
dc.identifier.issn1743-5390en_GB
dc.identifier.urihttp://dx.doi.org/10.1080/17435390.2017.1306894en_GB
dc.identifier.urihttp://publications.jrc.ec.europa.eu/repository/handle/JRC105653-
dc.description.abstractThe biokinetics of a size-selected fraction (70nm median size) of commercially available and 48V-radiolabeled [48V]TiO2 nanoparticles has been investigated in healthy adult female Wistar-Kyoto rats at retention time-points of 1h, 4h, 24h, 7d and 28d after intratracheal instillation of a single dose of an aqueous [48V]TiO2-nanoparticle suspension. A completely balanced quantitative biodistribution in all organs and tissues was obtained by applying typical [48V]TiO2-nanoparticle doses in the range of 40-240 μg·kg-1 bodyweight and making use of the high sensitivity of the radiotracer technique. The [48V]TiO2-nanoparticle content was corrected for residual blood retained in organs and tissues after exsanguination and for 48V-ions not bound to TiO2-nanoparticles. About 4% of the initial peripheral lung dose passed through the air-blood-barrier after 1h and were retained mainly in the carcass (4%); 0.3% after 28d. Highest organ fractions of [48V]TiO2-nanoparticles present in liver and kidneys remained constant (0.03%). [48V]TiO2-nanoparticles which entered across the gut epithelium following fast and long-term clearance from the lungs via larynx increased from 5-20% of all translocated/absorbed [48V]TiO2-nanoparticles. This contribution may account for 1/5 of the nanoparticle retention in some organs. After normalizing the fractions of retained [48V]TiO2-nanoparticles to the fraction that reached systemic circulation, the biodistribution was compared with the biodistributions determined after IV-injection (Part-1) and gavage (Part-2). The biokinetics patterns after IT instillation and gavage were similar but both were distinctly different from the pattern after intravenous injection disproving the latter to be a suitable surrogate of the former applications. Considering chronic occupational inhalation of minimally dissolving TiO2-particles (including nanoparticles) and accumulation in secondary organs may pose long-term health risks to be scrutinized more comprehensively.en_GB
dc.description.sponsorshipJRC.F.2-Consumer Products Safetyen_GB
dc.format.mediumPrinteden_GB
dc.languageENGen_GB
dc.publisherTAYLOR & FRANCIS LTDen_GB
dc.relation.ispartofseriesJRC105653en_GB
dc.titleQuantitative biokinetics of titanium dioxide nanoparticles after intratracheal instillation in rats (Part 3)en_GB
dc.typeArticles in periodicals and booksen_GB
dc.identifier.doi10.1080/17435390.2017.1306894en_GB
JRC Directorate:Health, Consumers and Reference Materials

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.